[1]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2005/118568,2005,A1Locationinpatent:Page/Pagecolumn22-23
[1]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2005/118568,2005,A1Locationinpatent:Page/Pagecolumn24
[1]CurrentPatentAssignee:ROCHEHOLDINGAG-WO2008/74697,2008,A1Locationinpatent:Page/Pagecolumn18
[2]CurrentPatentAssignee:NOEMAPHARMA-WO2022/23519,2022,A1Locationinpatent:Paragraph00120
[3]CurrentPatentAssignee:NOEMAPHARMA-WO2022/23519,2022,A1Locationinpatent:Paragraph00120
[1]Jaeschke,Georg;Kolczewski,Sabine;Spooren,Will;Vieira,Eric;Bitter-Stoll,Nadia;Boissin,Patrick;Borroni,Edilio;Büttelmann,Bernd;Ceccarelli,Simona;Clemann,Nicole;David,Beatrice;Funk,Christoph;Guba,Wolfgang;Harrison,Anthony;Hartung,Thomas;Honer,Michael;Huwyler,Jörg;Kuratli,Martin;Niederhauser,Urs;Pähler,Axel;Peters,Jens-Uwe;Petersen,Ann;Prinssen,Eric;Ricci,Antonio;Rueher,Daniel;Rueher,Marianne;Schneider,Manfred;Spurr,Paul;Stoll,Theodor;Tännler,Daniel;Wichmann,Jürgen;Porter,RichardH.;Wettstein,JosephG.;Lindemann,Lothar[JournalofMedicinalChemistry,2015,vol.58,#3,p.1358-1371]
Title: Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.
Journal: Journal of medicinal chemistry 20150212
Title: CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor.
Journal: The Journal of pharmacology and experimental therapeutics 20111101
Title: Lindemann L, et al. Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. J Pharmacol Exp Ther. 2015 Apr;353(1):213-33.
Title: Jaeschke G, et al. Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4--(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynylpyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases.